Martin Fassnacht
Endocrinology — University Hospital Würzburg, Germany
Martin Fassnacht
LeadR Profile
Endocrinology
Subspecialties: Oncology - Pharmacy - Pediatrics
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2000 - 2026
Number : 806
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Atrial Natriuretic Peptide Regulates Zona Glomerulosa Growth and Aldosterone Release. cells, hypertension, zona glomerulosa, aldosterone, growth, cytochrome p-450 cyp11b2, homeostasis, heart, communication, hyperaldosteronism, diet, herpes zoster, natriuretic peptides, atrial natriuretic factor, hemodynamics | Hypertension | 2026 | 0 |
| Does Automated Versus Manual Ki67 Labeling Index Assessment Influence Risk Stratification in Patients with Localized Adrenocortical Carcinoma? Lessons from the ADIUVO Trial. neoplasms, adrenocortical carcinoma, mitotane, prognosis | Cancers (Basel) | 2026 | 0 |
| Impact of adrenalectomy on metabolic alterations and quality of life in mild autonomous cortisol secretion: results from the randomized CHIRACIC trial. diabetes mellitus, hypertension, quality of life, comorbidity, conservative treatment, dyslipidemias, hormones, adrenalectomy, body weight, obesity, therapeutics, overweight, hydrocortisone, endocrine system diseases | Eur J Endocrinol | 2026 | 0 |
| Baseline biochemical evaluation for etiologic differentiation in ACTH-dependent Cushing's syndrome: machine learning and composite score analysis in a multicenter cohort of 566 patients. algorithms, hormones, machine learning, learning, adrenocorticotropic hormone, endocrine system diseases, cushing syndrome, sensitivity and specificity | Eur J Endocrinol | 2026 | 0 |
| PYY 3-36 potentiates Semaglutide‑mediated mitochondrial modulation in MASLD. genes, respiration, mitochondria, therapeutics, semaglutide | Am J Physiol Endocrinol Metab | 2026 | 0 |
Clinical Studies 30
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 3
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A randomized placebo controlled trial to evaluate the safety and efficacy of Debio 4126 in patients with acromegaly previously treated with somatostatin analogs 2024-516616-24-00 — somatostatin, safety, acromegaly, octreotide | Phase 3 | Recruiting | 2025 |
| Belzutifan MK 6482 for the Treatment of Advanced Pheochromocytoma Paraganglioma (PPGL) Pancreatic Neuroendocrine Tumor (pNET) Von Hippel Lindau (VHL) Disease Associated Tumors Advanced Gastrointestinal Stromal Tumor (wt GIST) or Solid Tumors With HIF 2 Related Genetic Alterations (MK 6482 015) NCT04924075 — cells, paraganglioma, islets of langerhans, safety, gastrointestinal stromal tumors, von hippel-lindau disease, pheochromocytoma, neoplasms, adenoma, islet cell, response evaluation criteria in solid tumors, neuroendocrine tumors, adenoma, therapeutics, neuroectodermal tumors, primitive | Phase 2 | Recruiting | 2021 |
LeadR Networks
Main global connection map